Aims: This study examined 448 Campylobacter strains isolated in 1999 and 2000 from US feedlot cattle for resistance to 12 antimicrobials. Methods and Results: Isolates were tested for antimicrobial susceptibility using the E-test method. Approximately 60% (n ¼ 267) were resistant to one or more antimicrobials, and 19AE6% (n ¼ 88) were resistant to two or more antimicrobials. Of the Campylobacter jejuni isolates, 49AE1% (n ¼ 187) were resistant to tetracycline, 10AE2% (n ¼ 39) were resistant to nalidixic acid, 8AE4% were resistant to trimethoprim/sulfamethoxazole, and 1AE8% (n ¼ 7) were resistant to ciprofloxacin. Resistance to any of the other eight antimicrobials was 1AE3% or less, but 14AE4% (n ¼ 55) were resistant to two or more antimicrobials. In the Campylobacter coli group, 65AE7% (n ¼ 44) were resistant to tetracycline, 52AE2% (n ¼ 35) were resistant to trimethoprim/sulfamethoxazole, 22AE4% (n ¼ 15) were resistant to nalidixic acid, and 9AE0% (n ¼ 6) were resistant to ciprofloxacin. Resistance to any of the remaining eight antimicrobials was 3AE0% or less, although 49AE3% (n ¼ 33) were resistant to two or more antimicrobials. Conclusions: Although antimicrobials are widely used in US feedlot cattle production, our results demonstrate generally low levels of resistance to a broad range of commonly used antimicrobials relative to other recent studies. Significance and Impact of the Study: Resistance data on Campylobacter isolated from this major US livestock commodity is lacking. This overview enhances current knowledge and provides a basis for further studies.
INTRODUCTION
Campylobacter is recognized as a major cause of acute bacterial gastroenteritis in humans worldwide (Friedman et al. 2000) . Clinical signs include abdominal pain, fever, malaise, nausea, vomiting and diarrhoea (Skirrow and Blaser 2000) . Most patients recover in less than a week, but up to 20% may relapse or experience prolonged or severe illness requiring antibiotic therapy. Two species of Campylobacter, C. jejuni and C. coli, are most frequently isolated from cases of human infection (Engberg et al. 2000) .
A number of studies have investigated the epidemiology of Campylobacter in poultry breeder and broiler operations (van de Giessen et al. 1992; Humphrey et al. 1993; JacobsReitsma 1995 JacobsReitsma , 1997 JacobsReitsma , 2000 Pearson et al. 1996) , and poultry products are considered to be a main source of Campylobacter infections in humans (Deming et al. 1987; Doyle and Jones 1992) . Prevalence studies have also shown that Campylobacter is a common commensal in cattle (Garcia et al. 1985; Manser and Dalziel 1985; Stanley et al. 1998; Wesley et al. 2000) . Accordingly, beef and dairy products (especially raw milk) can be a source of human Campylobacter infection (Stern 1992; Headrick and Tollefson 1998) .
The emergence of strains of Campylobacter and other food-borne bacterial pathogens resistant to antimicrobials used to treat human disease has provoked controversy over the use of antimicrobials in food animal production, including extensive examination of its effects on antimicrobial resistance in these organisms (Khachatourians 1998; Teuber 2001) . Antimicrobial resistance in Campylobacter isolated from the poultry production environment has been well documented in studies from around the world (JacobsReitsma et al. 1994; Chuma et al. 2001; Heuer et al. 2001; Van Looveren et al. 2001) . In contrast, while cattle have been included in multi-species investigations (Aarestrup et al. 1997; Piddock et al. 2000) , reports are lacking on antimicrobial resistance in Campylobacter isolated from cattle.
This study examined resistance to 12 common antimicrobials among a geographically diverse group of Campylobacter strains isolated in 1999 and 2000 from US feedlot cattle.
MATERIALS AND METHODS

Study design, and bacterial isolation and identification
The Campylobacter isolates used were collected as part of the 1999 National Animal Health Monitoring System study of the health and management of US feedlot cattle (Feedlot Ô99; USDA 2000). The study focused on feedlots with 1000 head or more capacity as these facilities held over 80% of US cattle as of February 1999. Faecal samples were obtained from 73 feedlots in 11 major US feedlot states: California, Colorado, Idaho, Iowa, Kansas, Nebraska, New Mexico, Oklahoma, South Dakota, Texas and Washington. Samples were collected during a 1-year period (October 1999 through September 2000) from pen floors. For each feedlot, 25 samples were collected from three pens. Feedlots were sampled twice during the 1-year collection period. Samples were shipped for overnight delivery to the USDA-ARS-ARRU laboratory in Athens (GA, USA) for isolation of Campylobacter and Salmonella.
For Campylobacter isolation, faecal samples were diluted 1 : 4 and 1 : 40 in phosphate-buffered saline. One hundredmicrolitre aliquots of each dilution were spread uniformly on duplicate Campy-Cefex plates . The plates were placed in zip-top bags and incubated microaerobically (5% O 2 , 10% CO 2 and 85% N 2 ) for 48 h at 42°C. Campylobacter was presumptively identified from microscope wet mounts of cells using phase contrast optics at 100·.
For the present study, a total of 448 isolates comprising 43AE5% (448 of 1029) of all the Feedlot Ô99 Campylobacter strains were randomly selected from among the frozen stock Feedlot Ô99 culture collection. Isolates included were derived from 67AE1% (49 of 73) of all feedlots sampled with some isolates from each of the 11 states where sampling occurred. Cultures were streaked onto Campy-Cefex plates, and incubated microaerobically for 48 h at 42°C. Isolated colonies were picked from these plates, streaked again onto Campy-Cefex plates, and incubated microaerobically for 48 h at 42°C. Isolated colonies from these plates were streaked onto trypticase soya agar plates containing 5% sheep's blood (BA plates; B-D Biosciences, Sparks, MD, USA), and incubated as before for 48 h at 42°C. The BA plates were used for isolate testing and to prepare additional frozen stock cultures. Isolates were identified using the Campylobacter BAXÒ PCR (DuPont Qualicon, Wilmington, DE, USA), a multiplex assay specific for C. coli and C. jejuni. The assay was performed according to the manufacturer directions as previously described (Englen and Fedorka-Cray 2002) .
Antimicrobial susceptibility testing
Isolates were tested for antimicrobial susceptibility using the E-test (AB-Biodisk, Piscataway, NJ, USA) according to the manufacturer directions. This method has been adopted by the National Antimicrobial Resistance Monitoring System (NARMS) for susceptibility testing of Campylobacter, in part, because it facilitates screening large numbers of isolates. It has been shown to give results comparable with other methods such as agar dilution for Campylobacter (Luber et al. 2003; Oncul et al. 2003) . In brief, 150 mm Mueller-Hinton + 5% lysed horse blood plates (B-D Biosciences) were inoculated with 100 ll of a cell suspension equivalent to 1AE0 McFarland standard. The inoculum was swabbed evenly across the entire plate surface. E-test strips were brought to room temperature from )20°C storage before use. Four strips were laid at 90°angles onto each plate. The plates were placed in zip-top bags and incubated microaerobically for 48 h at 42°C. Following incubation, the point at which the zone of growth inhibition intersected the strip was read as the minimum inhibitory concentration (MIC) of the antimicrobial in lg ml )1 . Quality control ATCC strains C. jejuni 33560, Escherichia coli 25922 and Staphylococcus aureus 25923 were tested biweekly to confirm susceptibility to all the antimicrobials. The antimicrobials used in the study and the resistance breakpoints (MICs) were: amoxicillin/clavulanic acid, ‡32; azithromycin, ‡2; cefepime, ‡32; chloramphenicol, ‡32; ciprofloxacin, ‡4; clindamycin, ‡4; erythromycin, ‡8; gentamicin, ‡16; imipenem, ‡16; nalidixic acid, ‡32; tetracycline, ‡16; trimethoprim/sulfamethoxazole, ‡32. With the exception of cefepime, the MICs for the respective resistance breakpoints were those used by NARMS as reported in the US Centers for Disease Control NARMS 2001 Annual Report (http:// www.cdc.gov/narms/annuals.htm). For cefepime, the E-test manufacturer's recommended resistance breakpoint for anaerobes was used.
Data analysis
The antimicrobial resistance data was analysed using the proportional hazard model (PHREG) in the SAS statistical program (SAS Institute, Cary, NC, USA). This method performs conditional logistic regression and provides adjustment for the fact that the 448 isolates (i.e. observations) were not entirely independent. Rather, the isolates were obtained from 73 different feedlots, with some imbalance between the proportion of C. coli and C. jejuni observed in each feedlot. This method and its applications are discussed in detail by Allison (1999) .
RESULTS
Antimicrobial resistance
Approximately 60% (n ¼ 267) of the 448 isolates included in the study were resistant to one or more antimicrobials. The percentages by species of isolates resistant to the individual antimicrobials are shown in Table 1 . The greatest level of resistance observed was to tetracycline, at 51AE6% (n ¼ 231) for the test group as a whole. Resistance to trimethoprim/sulfamethoxazole was next highest, at 15AE0% (n ¼ 67) overall, followed by nalidixic acid at 12AE1% (n ¼ 54). The isolates showed much less resistance to the remaining nine antimicrobials. Among these, ciprofloxacin resistance was the greatest, although reaching only 2AE9% (n ¼ 13). However, a number of differences in antimicrobial resistance were observed between species (Table 1) . In particular, resistance in the C. coli group to nalidixic acid was more than twice as high as for the C. jejuni group (22AE4%, n ¼ 15 vs 10AE2%, n ¼ 39; P < 0AE05), and five times higher for ciprofloxacin, compared with the C. jejuni strains (9AE0%, n ¼ 6 vs 1AE8%, n ¼ 7; P < 0AE05). Similarly, resistance to trimethoprim/sulfamethoxazole was observed in 52AE2% of the C. coli (n ¼ 35) isolates, more than six times that of C. jejuni (8AE4%, n ¼ 32; P < 0AE05). The C. coli isolates were also more resistant to tetracycline than the C. jejuni strains (65AE7%, n ¼ 44 vs 49AE1%, n ¼ 187), although this difference was not significant at the 5% level.
Multiple resistance
Of the 448 isolates tested, 19AE6% (n ¼ 88) were resistant to two or more antimicrobials. A significantly higher percentage of the C. coli strains (49AE3%, n ¼ 33; P < 0AE05) belonged to this group compared with the C. jejuni isolates (14AE4%, n ¼ 55). The majority of these 88 strains (71AE6%, n ¼ 63) were resistant to just two antimicrobials (Table 2) . Of the 63 isolates resistant to two antimicrobials, 49AE2% (n ¼ 31; 14 C. jejuni and 17 C. coli) combined resistance to tetracycline and trimethoprim/sulfamethoxazole. The next most common pattern was resistance to nalidixic acid and tetracycline, found in 39AE7% (n ¼ 25; 24 C. jejuni and one C. coli) of these strains. The remaining four patterns of double resistance were comprised of three or fewer isolates. (67) *Significantly higher resistance (P < 0AE05) compared with C. jejuni. Resistance to three or more antimicrobials was found in 28AE4% (n ¼ 25) of the 88 multi-resistant isolates or 5AE6% of all isolates (Table 2) . Significantly, seven times more C. coli were found in this group compared with the C. jejuni strains (20AE9%, n ¼ 14 vs 2AE9%, n ¼ 11; P < 0AE05). Among the 11 resistance patterns found for those isolates resistant to three or more antimicrobials, two were more common. Most frequently observed was the combination of nalidixic acid, tetracycline and trimethoprim/sulfamethoxazole resistance, found in 28% (n ¼ 7) of these 25 strains (Table 2) . Resistance to ciprofloxacin, nalidixic acid and tetracycline was observed in 24% (n ¼ 6) of this group. Moreover, a single C. jejuni isolate was found to be resistant to seven antimicrobials.
DISCUSSION
The use of antimicrobials in food animal production has become a source of great controversy in recent years. Concerns over the emergence of bacterial pathogens resistant to antimicrobials commonly used to treat infections in humans, and the potential transfer of resistant pathogenic strains from food products to humans has led to changes in antimicrobial usage in livestock and poultry production worldwide (Aarestrup and Wegner 1999; McEwen and Fedorka-Cray 2002) . Monitoring susceptibility patterns to important antimicrobials among pathogens isolated from food animal production sources is an essential component in assessing risk associated with antimicrobial use in agriculture. Antimicrobial susceptibility was examined in Campylobacter isolated from US feedlot cattle. To date, this livestock group has received relatively little attention in antimicrobial resistance-monitoring studies.
A high level of resistance was observed to tetracycline, exceeding 51% for the isolate group as a whole (Table 1) . This finding was not surprising as tetracyclines are commonly used as injectable therapeutics for respiratory disease, and as feed or water additives during the feedlot stage of beef cattle production in the USA (USDA 2000). Among the Campylobacter species, tetracycline resistance was noticeably higher in C. coli, reaching nearly 66% compared with 49AE1% for C. jejuni. These numbers are substantially higher than the average reported in a recent multi-nation European study ) for tetracycline resistance in C. coli (41AE2%) and C. jejuni (19AE9%) from cattle. This may be a consequence of more limited overall use of this drug in the countries that provided the Campylobacter isolates (Germany, Italy and the UK).
In contrast, although it has been estimated that only c. 0AE3% of the cattle represented by the Feedlot Ô99 study received sulfonamides in the feed or water, the overall resistance to trimethoprim/sulfamethoxazole was 15AE0%. A study by Karmali et al. (1981) reported very high levels of resistance to trimethoprim and sulfamethoxazole (100 and 85% of the isolates, respectively, at 32 lg ml )1 ) in C. jejuni from human faecal isolates. Campylobacter jejuni has subsequently come to be regarded as endogenously resistant to trimethoprim . Nonetheless, resistance to trimethoprim/sulfamethoxazole among C. jejuni in our study was only 8AE4% (n ¼ 32) compared with 52AE2% (n ¼ 35) for the C. coli strains (Table 1) . Whether this indicates a greater propensity for C. coli to acquire resistance to trimethoprim/sulfamethoxazole compared with C. jejuni remains to be determined, although it is again reflective of the generally higher levels of resistance found in C. coli (this study).
The fluoroquinolone enrofloxacin is approved for use in the USA for the treatment of bovine respiratory disease in cattle, and c. 32% of the feedlots in the Feedlot Ô99 study reported using this antimicrobial therapeutically in some cattle (USDA 2000) . Still, resistance to ciprofloxacin, the active metabolite of enrofloxacin, was only 2AE9% overall, although in C. coli resistance was 9AE0% (Table 1) . Feedlot cattle are administered enrofloxacin as a single intramuscular injection (http://www.fda.gov/cvm/greenbook.html). Concentrations of an injected fluoroquinolone reaching the gut probably remain quite low. Resistance to ciprofloxacin was one-fourth that of nalidixic acid (2AE9 and 12AE1% respectively), a finding similar to that described by Aarestrup et al. (1997) for quinolone resistance in Campylobacter from cattle. Among species, nalidixic acid resistance in C. coli was more than twice that of C. jejuni (22AE4% vs 10AE2%). In contrast, Bywater et al. (2004) found relatively high resistance to ciprofloxacin in C. coli and C. jejuni from cattle (23AE5 and 13AE5% respectively), with comparable levels of resistance to nalidixic acid.
A primary mechanism of resistance to quinolones in Campylobacter involves discrete point mutations in the gyrA gene, which encodes DNA gyrase (a type II topoisomerase) (Drilca and Zhao 1997) . In particular, the frequently observed substitution Thr86-Ile in Campylobacter gyrA is known to confer cross-resistance to both ciprofloxacin and nalidixic acid (Wang et al. 1993; . Accordingly, 100% (n ¼ 13) of the ciprofloxacin-resistant isolates were also resistant to nalidixic acid. However, 41 isolates (32 C. jejuni and nine C. coli), comprising 75AE9% of the 54 quinolone-resistant strains found in this study, were resistant to nalidixic acid but did not show cross-resistance to ciprofloxacin. The increased prevalence of nalidixic acid resistance compared with ciprofloxacin was surprising, considering that the feedlot cattle in this study were never treated with nalidixic acid. In US broiler production, enrofloxacin has been administered orally to flocks in the drinking water to control and treat colibacillosis associated with E. coli infection (http://www.fda.gov/cvm/ greenbook.html). Similarly, higher levels of resistance to nalidixic acid compared with ciprofloxacin have been reported for the NARMS Campylobacter poultry isolates (http://www.ars-grin.gov/ars/SoAtlantic/Athens/ arru/narms.html), the source of which is broiler carcasses. Bachoual et al. (2001) found that the Thr86-Ala gyrA substitution in C. jejuni resulted in resistance to nalidixic acid (MIC 64 lg ml )1 ) but not to ciprofloxacin (MIC 2 lg ml )1 ). This may explain the observed differences for ciprofloxacin and nalidixic acid resistance, although other mechanisms such as active efflux might also be involved.
Macrolides, in particular tilmicosin and tylosin, are also frequently used in injectable form as therapeutics, and tylosin was used as a feed or water additive on 20% of the feedlots represented in the Feedlot Ô99 study of health and management in US feedlots (USDA 2000) . However, resistance did not exceed 1AE1% for the test group overall to any of the three macrolide/lincosamide agents (azithromycin, clindamycin and erythromycin) included in this study (Table 1) . Cross-resistance to these antimicrobials in strains resistant to tilmicosin or tylosin might be expected, as discrete point mutations in the 23S rRNA gene appear to be the primary mechanism involved in macrolide resistance in Campylobacter (Engberg et al. 2001; Vacher et al. 2003) . Nonetheless, resistance to erythromycin, still considered a drug of choice for treating Campylobacter infection, was only 0AE9% overall (Table 1) . Moreover, macrolide resistance was far less than has been observed in Campylobacter from swine (Aarestrup et al. 1997; Sáenz et al. 2000; Van Looveren et al. 2001; Bywater et al. 2004) , even though drugs of this class are commonly used in both cattle and swine production. This indicates that even relatively high usage of antimicrobials in particular class of food animals does not necessarily lead to high levels of resistance to related antimicrobials important in human medicine.
Although the use of chloramphenicol in livestock production has been banned for many years in the USA, a fluorinated derivative, florfenicol, is approved for use in treating respiratory disease in feedlot cattle. Of the feedlots represented in the Feedlot Ô99 study, 54% used florfenicol as a treatment for respiratory disease in some cattle, and 22AE1% used florfenicol metaphylactically to control shipping fever in some cattle (USDA 2000) . Cross-resistance to florfenicol and chloramphenicol has been reported in E. coli and Salmonella (Bolton et al. 1999) resulting from the acquisition of a unique gene termed flo. Resistance to chloramphenicol in Campylobacter is most commonly mediated by chloramphenicol acetyltransferase which inactivates the drug by acetylation (Wang and Taylor 1990) . This mechanism does not confer cross-resistance to florfenicol (Keyes et al. 2000) . The lack of selective pressure by florfenicol would account for the low overall resistance (1AE3%; Table 1) observed to chloramphenicol.
The majority of Campylobacter isolates show resistance to penicillins and narrow spectrum cephalosporins (Tajada et al. 1996; Treiber and Taylor 2000) , but this activity rarely extends to the newer b-lactam agents. Consistent with this observation, resistance to imipenem, cefepime and amoxicillin/clavulanic acid did not exceed 1AE3% (Table 1) although cephalosporins and penicillin/amoxicillin were used in 8-38% of feedlots to treat some cases of respiratory disease (USDA 2000) .
Aminoglycosides, including gentamicin, are not generally used to treat beef cattle in the USA, due to, in part, the long duration of drug residues in some tissues. Not surprisingly, only a single isolate among the 448 Campylobacter strains included in this study was resistant to gentamicin.
Multiple resistance, including all isolates resistant to two or more antimicrobials, was found more than three times as often in the C. coli strains (49AE3%; 33 of 67) compared with the C. jejuni isolates (14AE4%; 55 of 381). Moreover, resistance to three or more antimicrobials, found in 5AE6% (25 of 448) of all isolates (Table 2) , was over seven times more common among the C. coli isolates (20AE9%; 14 of 67) compared with C. jejuni (2AE9%; 11 of 381). Multidrug resistance in Campylobacter has recently been reported to be associated with the expression of the cmeABC efflux system (Randall et al. 2003) . While it may be speculated that this system is expressed more often in certain Campylobacter species such as C. coli, further work will be required to fully explain this observation. Among the isolates resistant to three or more antimicrobials, few patterns were apparent. However, we noted that ciprofloxacin resistance in this group was primarily associated with tetracycline resistance (Table 2 ). This association has been seen in previous studies, although the genetic basis has not been described (Piddock 1995; Gaunt and Piddock 1996) . Resistance to macrolides among the multi-resistant isolates showed a mixture of patterns. Specifically, resistance to azithromycin and clindamycin or azithromycin and erythromycin was observed, as well as resistance to only clindamycin or erythromycin (Table 2) . Only one strain in this group was resistant to azithromycin, clindamycin and erythromycin, an unusual C. jejuni isolate resistant to seven antimicrobials. Although the mechanisms involved in macrolide resistance in Campylobacter are not fully defined, cross-resistance to azithromycin, clindamycin and erythromycin might have been expected to be more commonly observed based on previous reports (Engberg et al. 2001; Vacher et al. 2003) .
In conclusion, despite the widespread use of antimicrobials in US feedlot cattle production, generally low levels of antimicrobial resistance were observed in Campylobacter isolated from this livestock source. A recent review of European antimicrobial susceptibility surveillance results by Bywater (2004) also noted that Campylobacter isolates from cattle showed lower levels of resistance compared with broiler and swine carcass isolates. Tetracycline resistance was an exception, although high levels of resistance to this drug are often found in Campylobacter from food production animals (e.g. Sáenz et al. 2000; Van Looveren et al. 2001; Bywater et al. 2004) . Some of the differences reported on antimicrobial resistance in Campylobacter from various food animal sources may be attributed to the susceptibility test methods used (i.e. agar disk diffusion or agar dilution vs E-test), and to differences in actual drug use practices. Even so, obtaining antimicrobial resistance data from all food animal groups is essential to the development and management of rational antimicrobial use practices in food animal production.
